Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD? / Wadström, Benjamin N.; Wulff, Anders B.; Pedersen, Kasper M.; Nordestgaard, Børge G.

I: Current Atherosclerosis Reports, Bind 25, 2023, s. 795-803.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Wadström, BN, Wulff, AB, Pedersen, KM & Nordestgaard, BG 2023, 'Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?', Current Atherosclerosis Reports, bind 25, s. 795-803. https://doi.org/10.1007/s11883-023-01153-8

APA

Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023). Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD? Current Atherosclerosis Reports, 25, 795-803. https://doi.org/10.1007/s11883-023-01153-8

Vancouver

Wadström BN, Wulff AB, Pedersen KM, Nordestgaard BG. Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD? Current Atherosclerosis Reports. 2023;25:795-803. https://doi.org/10.1007/s11883-023-01153-8

Author

Wadström, Benjamin N. ; Wulff, Anders B. ; Pedersen, Kasper M. ; Nordestgaard, Børge G. / Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?. I: Current Atherosclerosis Reports. 2023 ; Bind 25. s. 795-803.

Bibtex

@article{629ea2c06ff14673958595ee28f50601,

title = "Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?",

abstract = "Purpose of Review: Recent large clinical trials have failed to show that triglyceride-rich lipoprotein-lowering therapies decrease the risk of atherosclerotic cardiovascular disease (ASCVD). In this review, we reconcile these findings with evidence showing that elevated levels of triglyceride-rich lipoproteins and the cholesterol they contain, remnant cholesterol, cause ASCVD alongside low-density lipoprotein (LDL) cholesterol. Recent Findings: Results from observational epidemiology, genetic epidemiology, and randomized controlled trials indicate that lowering of remnant cholesterol and LDL cholesterol decrease ASCVD risk by a similar magnitude per 1 mmol/L (39 mg/dL) lower non-high-density lipoprotein cholesterol (remnant cholesterol+LDL cholesterol). Indeed, recent guidelines for ASCVD prevention recommend the use of non-high-density lipoprotein cholesterol instead of LDL cholesterol. Summary: Current consensus is moving towards recognizing remnant cholesterol and LDL cholesterols as equals per 1 mmol/L (39 mg/dL) higher levels in the risk assessment of ASCVD; hence, triglyceride-rich lipoprotein-lowering therapies should also lower levels of non-HDL cholesterol to reduce ASCVD risk.",

keywords = "Chylomicrons, Intermediate-density lipoprotein, Ischemic, Major adverse coronary events, Triglycerides, Very-low-density lipoproteins",

author = "Wadstr{\"o}m, {Benjamin N.} and Wulff, {Anders B.} and Pedersen, {Kasper M.} and Nordestgaard, {B{\o}rge G.}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2023",

doi = "10.1007/s11883-023-01153-8",

language = "English",

volume = "25",

pages = "795--803",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Springer Healthcare",